Lanomycin

Amikacin sulfate, the active ingredient in Lanomycin, is an aminoglycoside antibiotic presented as a sterile powder for reconstitution for intramuscular and intravenous use. It treats severe infections caused by susceptible gram‑negative bacteria in adult and pediatric patients when other agents are unsuitable.

GNH USA supplies Lanomycin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lanomycin, an aminoglycoside antibiotic, is employed for serious infections caused by gram‑negative organisms.

- Severe gram‑negative infections: Provides rapid bactericidal activity against susceptible strains. - Sepsis: Contributes to systemic infection control when combined with appropriate therapy. - Hospital‑acquired pneumonia: Targets resistant pathogens in lower respiratory tract infections. - Urinary tract infections: Eradicates complicated UTIs caused by resistant gram‑negative bacteria. - Intra‑abdominal infections: Assists in managing polymicrobial abdominal sepsis.

Amikacin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nephrotoxicity: Elevated serum creatinine and reduced renal clearance. - Ototoxicity: Tinnitus or hearing loss, especially with prolonged use. - Vestibular dysfunction: Dizziness or balance disturbances. - Rash or mild skin eruption. - Fever without clear source.

Serious or Rare Side Effects: - Anaphylactic reaction: Rapid onset of airway compromise and hypotension. - Severe allergic dermatitis: Extensive skin involvement requiring medical intervention. - Respiratory distress: Bronchospasm or pulmonary edema. - Irreversible hearing loss: Permanent auditory damage. - Acute renal failure: Sudden loss of kidney function. - Neuromuscular blockade: Muscle weakness leading to respiratory failure.

Before initiating Lanomycin, clinicians should assess patient‑specific risk factors and monitor for toxicity.

- Renal function monitoring: Check serum creatinine and urine output before and during therapy. - Auditory assessment: Perform baseline and periodic hearing tests, especially in prolonged courses. - Dose adjustment in renal impairment: Reduce dose or extend interval based on glomerular filtration rate. - Avoid concurrent nephrotoxic agents: Limit use with vancomycin, loop diuretics, or contrast media. - Pregnancy caution: Category D; weigh maternal benefits against fetal risks. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Amikacin can interact with several drug classes, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Concurrent nephrotoxic antibiotics (e.g., vancomycin, gentamicin): Heightened risk of renal injury. - Ototoxic agents (e.g., furosemide, cisplatin): Amplified hearing loss. - Neuromuscular blocking drugs (e.g., succinylcholine): Potentiated muscle weakness.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: May exacerbate renal dysfunction. - NSAIDs: Can reduce renal clearance of amikacin. - Loop diuretics: Increase risk of ototoxicity when used together. - Antacids containing magnesium or aluminum: May affect absorption of other co‑administered oral drugs.